GL-V9 inhibits proliferation of HepG2 cell ( IC 50 is 35.2 μM) through induction of apoptosis and cell cycle arrest at G2/M phase. GL-V9 regulates mitochondrial membrane potential and increases the production of intracellular reactive oxygen species. GL-V9 inhibits the pentose phosphate pathway (PPP), enhances fatty acid oxidation (FAO) through activation of AMPK , and thus inhibits the metastasis of cancer cells. GL-V9 exhibits antitumor efficacy in mouse model.